Delivers Record Quarter of
M&A, Surpassing 500 Practices Acquired Since 2011
- Revenue of $280.2 million for the
first quarter 2022, an increase of 13.4% compared to the same
period last year
- Adjusted EBITDA(1) of $50.1
million for the first quarter 2022, an increase of 7.3%
compared to the same period last year; Adjusted EBITDA
margins(1) of 17.9% for the quarter
- Last 12-months PF Revenue(1) and PF Adjusted
EBITDA(1) of $1.2 billion
and $234.1 million, respectively; PF
Adjusted EBITDA margin(1) of 19.4%
- Acquired $25.0 million in PF
Adjusted EBITDA(1) from the acquisition of 42 practices
in the first quarter 2022, surpassing 500 practices acquired
nationwide since the Company's inception in 2011
- Adjusted Same Practice Sales Growth(1) of 2.7%;
Adjusted Free Cash Flow(1) of $40.4 million; Adjusted Net Income(1)
of $28.6 million; Net Loss of
$11.0 million, all for the first
quarter 2022
(1) Non-IFRS
financial measure, non-IFRS ratio or supplementary financial
measure. See "Non-IFRS and Other Measures" section of this news
release.
|
TORONTO, May 10, 2022
/CNW/ - dentalcorp Holdings Ltd. ("dentalcorp" or the
"Company") (TSX: DNTL), Canada's largest, and one of North America's fastest growing networks of
dental practices, announced today its three-month financial and
operating results for the period ended March
31, 2022. All references to dollar values in this press
release are in Canadian dollars, unless otherwise indicated.
"Our financial results again demonstrate the durability and
strength of our business," said Graham
Rosenberg, Chief Executive Officer. "Our team delivered
another strong quarter despite significant headwinds from Omicron.
During the first quarter, we completed a record 16 acquisitions
comprised of 42 locations, which are expected to generate
approximately $25.0 million in PF
Adjusted EBITDA. This rapid acquisition pacing reinforces
dentalcorp's position as the acquirer of choice for Canada's leading dental practices and results
from the significant investment we have made in our national
business development team and our automated integration
capabilities."
Mr. Rosenberg added, "This quarter marked a significant
milestone as we acquired our 500th practice and is a
testament to the trusting relationships we have built over the last
decade with our dentist partners and with the dental community more
broadly. We have the most robust pipeline in our history and we are
well on our way to delivering another year of strong double-digit
growth."
The Company has now successfully deployed the $115 million of gross proceeds raised through a
bought deal offering in January
2022.
Financial and Operating Results for the Three Months Ended
March 31, 2022
- Revenue for the first quarter 2022 was $280.2 million, an increase of $33.2 million or 13.4% over the first quarter
2021. The increase in revenue for the quarter was driven by
incremental revenue from acquired practices, offset by Same
Practice Sales Growth of (3.3%).
- Dental provider absences and patient cancellations from Omicron
had a significant impact on Same Practice Sales Growth over the
first quarter of 2021. When adjusting for these impacts, Adjusted
Same Practice Sales Growth during the period was 2.7%. dentalcorp
experienced sequential monthly growth through the first quarter
2022. This sequential growth has continued into April and early May
with Sales Practice Sales Growth substantially in line with Q1
without factoring in any Omicron impact. The Company continued to
generate a positive contribution from orthodontics insourcing with
217 practices in the ortho acceleration program versus 165 in the
first quarter 2021.
- Adjusted EBITDA increased by $3.4
million to $50.1 million in
the first quarter 2022 over the first quarter 2021, an increase of
7.3%.
- Adjusted EBITDA Margin decreased to 17.9% in the first quarter
2022 as capacity utilization was impacted by Omicron headwinds.
- Adjusted Free Cash Flow was $40.4
million for the first quarter 2022 compared to $14.9 million for the first quarter 2021.
- Adjusted Net Income for the first quarter 2022 was $28.6 million, compared to $12.5 million for the first quarter 2021.
- The Company acquired 42 dental practices during the first
quarter 2022, which are budgeted to generate a total of
approximately $25.0 million in PF
Adjusted EBITDA, for total consideration of $220 million. As at March
31, 2022, the Company owned 500 dental practices compared to
412 practices at March 31, 2021.
- The Company ended the first quarter 2022 with liquidity of
$514.3 million, comprised of
$164.3 million in cash and
$350.0 million in debt capacity under
its $1.3 billion Senior Debt
facility. Approximately $950.0
million of its Senior Debt facility was drawn at quarter
end.
- As previously disclosed, the Company completed a bought deal
offering for total gross proceeds of $115.0
million. The proceeds were used to fund outpaced,
acquisitive growth, driven by accretive, mid-market deals. The
Company closed a portion of these transactions in the first quarter
2022, with additional mid-market platforms expected to close in the
second quarter 2022. The Company continues to be in position to
capitalize on a fragmented market and drive sustained growth
through its strong M&A pipeline.
Subsequent to Quarter End:
- dentalcorp and Risio Institute formed an exclusive partnership
to train new Certified Dental Assistants across the dentalcorp
network. This innovative partnership will allow students to learn
through a high-quality online curriculum, while continuing to
work.
- The Company partnered with the University
of Alberta School of Dentistry to support student
well-being, and access to financial aid and education. The
partnership will be recognized by naming facilities at the
University of Alberta School as the
dentalcorp Student Lab, and the dentalcorp Simulation
Lab.
- dentalcorp was recognized as one of Canada's Best Managed Companies for the eighth
year in a row, and the second year as a Platinum Club member.
Canada's Best Managed Companies
continues to be the mark of excellence for Canadian-owned and
managed companies with revenues over $50
million.
Consolidated Financial Results
|
Three months
ended
|
|
March
31,
|
|
March
31,
|
|
2022
|
|
2021
|
|
$
|
|
$
|
|
(expressed in
millions)
|
Statements of Loss
and Comprehensive loss:
|
|
|
|
Revenue
|
280.2
|
|
247.0
|
Cost of
revenue
|
141.1
|
|
125.6
|
Gross
Profit
|
139.1
|
|
121.4
|
Selling, general and
administrative expenses
|
94.4
|
|
83.3
|
Depreciation and
amortization
|
41.5
|
|
37.9
|
Share-based
compensation
|
5.6
|
|
2.6
|
Foreign exchange
gain
|
—
|
|
(17.9)
|
Net finance
costs
|
11.1
|
|
39.6
|
Change in fair value of
derivative instruments
|
—
|
|
13.4
|
Change in fair value of
contingent consideration
|
11.0
|
|
(3.9)
|
Change in fair value of
conversion option
|
—
|
|
(19.8)
|
Loss before income
taxes
|
(24.5)
|
|
(13.8)
|
Income tax
recovery
|
(13.5)
|
|
(4.8)
|
Net loss and
comprehensive loss
|
(11.0)
|
|
(9.0)
|
Other Metrics
Adjusted Net
Income
|
28.6
|
|
12.5
|
Adjusted
EBITDA
|
50.1
|
|
46.7
|
For the definition of Adjusted Net Income and a reconciliation
to Net Income, see Non-IFRS measures below.
For the definition of Adjusted EBITDA and a reconciliation to
EBITDA, see Non-IFRS measures below.
Outlook
dentalcorp continues to reinforce its position as the acquirer
of choice for leading dentists, and demonstrate its ability to add
value to acquired dental practices. With 745+ total opportunities
in its pipeline, and 200+ opportunities in more advanced stages of
negotiation, dentalcorp expects to maintain its path of delivering
sustained double-digit growth.
dentalcorp experienced sequential monthly increases in Same
Practice Sales Growth during the first quarter 2022 and through
April 2022. When combining this trend
with the Company's strong ongoing acquisitive growth program, the
Company expects to deliver double-digit revenue growth in the
second quarter 2022 over the first quarter 2022 and with strong
Same Practice Sales Growth over the comparable period in 2021.
Conference Call Notification
The Company will hold a conference call to provide a corporate
update on Tuesday, May 10, 2022, at
8:30 a.m. ET. A question-and-answer
session will follow the corporate update.
CONFERENCE CALL
DETAILS
|
|
|
DATE:
|
Tuesday, May 10,
2022
|
|
|
TIME:
|
8:30 a.m. ET
|
|
|
DIAL-IN
NUMBER:
|
416-764-8650 or
1-888-664-6383
|
|
|
TAPED
REPLAY:
|
416-764-8677 or
1-888-390-0541
|
|
|
REFERENCE
NUMBERS:
|
78476939 (live call);
476939# (taped replay)
|
This call is being webcast and can be accessed by going to:
https://produceredition.webcasts.com/starthere.jsp?ei=1543304&tp_key=ff139c42ff
An archived replay of the webcast will be available for two
weeks by clicking the link above.
Reminder of Annual General Meeting
The Company will hold its annual general meeting ("AGM") of
shareholders virtually on May 26th, 2022, at 11:00 am
ET.
Further information regarding the AGM is set forth in the Notice
of Meeting and Record Date filed on SEDAR on March 17,
2022, and in the management information circular filed on
SEDAR.
Non-IFRS and Other Measures
As appropriate, we supplement our results of operations
determined in accordance with IFRS with certain non-IFRS financial
measures that we believe are useful to investors, lenders, and
others in assessing our performance and which highlight trends in
our core business that may not otherwise be apparent when relying
solely on IFRS measures. Our management also uses non-IFRS measures
for purposes of comparison to prior periods, to prepare annual
operating budgets, for the development of future projections and
earnings growth prospects, to measure the profitability of ongoing
operations and in analyzing our financial condition, business
performance and trends, including the run-rate of the business
after taking into consideration the acquisitions of dental
practices. As such, these measures are provided as additional
information to complement those IFRS measures by providing further
understanding of our results of operations from management's
perspective, including how we evaluate our financial performance
and how we manage our capital structure. We also believe that
securities analysts, investors, and other interested parties
frequently use these non-IFRS measures and industry metrics in the
evaluation of issuers. These non-IFRS measures are not recognized
measures under IFRS and do not have a standardized meaning
prescribed by IFRS and may include or exclude certain items as
compared to similar IFRS measures, and such measures may not be
comparable to similarly-titled measures reported by other
companies. Accordingly, these measures should not be considered in
isolation nor as a substitute for analysis of our financial
information reported under IFRS.
During the three months ended March 31,
2022, the Company changed the composition of "Adjusted
EBITDA" to (i) remove the Canada
Emergency Wage Subsidy ("CEWS") to reflect that the adjustment to
EBITDA related to CEWS was not applicable for the three months
ended March 31, 2022 and 2021, and
(ii) to remove the loss on disposal of property and equipment as
the adjustment to EBITDA was not applicable for the three months
ended March 31, 2022 and 2021.
The composition of "Adjusted net income" and "Adjusted free cash
flow" were each changed to (i) remove the CEWS to reflect that the
adjustment to (a) net income and comprehensive income and (b) cash
flow from operating activities arising from CEWS, was not
applicable for the three months ended March
31, 2022 and 2021, and (ii) to remove the adjustment for
legacy debt, net of tax impact as the adjustment to (a) net income
and comprehensive income and (b) cash flow from operating
activities arising from the legacy debt, was no longer applicable
for the three months ended March 31,
2022. "Adjustment for legacy debt" relates to (i) a
reduction of cash interest due to lower interest rates on the
Credit Facilities and lower overall level of borrowings, (ii)
non-cash losses related to the refinancing of the Company's
borrowings; and (iii) the realized foreign exchange impact on the
Company's draw-downs and repayments under the Pre-IPO
Borrowings.
The Company also changed the composition of "PF Adjusted EBITDA"
and "PF Revenue" to remove the estimated impact of the COVID-19
related closures on the Company as the adjustment arising from the
estimated impact of the COVID-19 related closures was no longer
applicable for the three months ended March
31, 2022 and 2021.
EBITDA
"EBITDA" means, for the applicable period, net loss and
comprehensive loss plus (a) net finance costs, (b) income tax
expense (recoveries), and (c) depreciation and amortization. We
present EBITDA to assist investors in understanding the
mathematical development of Adjusted EBITDA. Management does not
use EBITDA as a financial performance metric. For more information
on how EBITDA is calculated, see below.
|
Three months
ended
|
|
March
31,
|
|
March
31,
|
|
2022
|
|
2021
|
|
$
|
|
$
|
|
(expressed in
millions)
|
Net loss and
comprehensive loss
|
(11.0)
|
|
(9.0)
|
Add:
|
|
|
|
Net finance
costs
|
11.1
|
|
39.6
|
Income tax
recovery
|
(13.5)
|
|
(4.8)
|
Depreciation and
amortization
|
41.5
|
|
37.9
|
EBITDA
|
28.1
|
|
63.7
|
Adjusted EBITDA
"Adjusted EBITDA" is calculated by adding to EBITDA certain
expenses, costs, charges or benefits incurred in such period which
in management's view are either not indicative of underlying
business performance or impact the ability to assess the operating
performance of our business, including: (a) net impact of foreign
exchange, change in fair value of derivative instruments, change in
fair value of conversion option, and share of associate losses; (b)
share-based compensation; (c) external acquisition expenses; (d)
COVID-19 costs; (e) change in fair value of contingent
consideration; (f) one-time costs related to the IPO; and (g) other
one-time corporate costs (consisting primarily of consulting costs
related to our recent Enterprise Resource Planning ("ERP")
implementation). Adjusted EBITDA is a supplemental measure used by
management and other users of our financial statements to assess
the financial performance of our business without regard to the
effects of interest, depreciation and amortization costs, expenses
that are not considered reflective of underlying business
performance, and other expenses that are expected to be one-time or
non-recurring. We use Adjusted EBITDA to facilitate a comparison of
our operating performance on a consistent basis from period to
period and to provide for a more complete understanding of factors
and trends affecting our business. Adjusted EBITDA is not an IFRS
measure. For more information on how Adjusted EBITDA is calculated,
see below.
|
Three months
ended
|
|
March
31,
|
|
March
31,
|
|
2022
|
|
2021
|
|
$
|
|
$
|
|
(expressed in
millions)
|
EBITDA
|
28.1
|
|
63.7
|
Add:
|
|
|
|
Net impact of foreign
exchange, change in fair value of derivatives, change in fair value
of
conversion option, and share of associate losses
|
—
|
|
(24.3)
|
Share-based
compensation
|
5.6
|
|
2.6
|
External acquisition
expenses(1)
|
4.2
|
|
1.0
|
COVID-19
costs(2)
|
—
|
|
1.0
|
Change in fair value of
contingent consideration(3)
|
11.0
|
|
(3.9)
|
IPO costs
|
—
|
|
5.9
|
Other corporate
costs(4)
|
1.2
|
|
0.7
|
Adjusted
EBITDA
|
50.1
|
|
46.7
|
|
|
1.
|
Represents professional
fees and other expenses paid to third parties related to practice
acquisitions. These costs are excluded as they are incurred in
connection with each practice acquisition and are not related to
underlying business operations of the Company.
|
2.
|
Represents costs
incurred as a result of the COVID-19 pandemic that are not expected
to recur, including additional employee benefits and retention
payments to staff, retrofitting expenses at practices, and payments
to safety consultants. The Company's cost of revenue was also
impacted in 2021 due to the normalization of the cost of consumable
inventories from previously inflated rates as a result of
COVID-19.
|
3.
|
On acquisition, and at
each subsequent reporting date, obligations under earn-out
arrangements are measured at fair value with the changes in fair
value recognized in the consolidated statements of loss or
comprehensive loss.
|
4.
|
Represents costs
related to the implementation of new corporate systems and the
undertaking of vendor consolidations.
|
Adjusted EBITDA Margin
"Adjusted EBITDA Margin" means Adjusted EBITDA divided by
revenue. Adjusted EBITDA Margin is not an IFRS measure.
PF Revenue
"PF Revenue" in respect of a period means revenue for that
period plus the Company's estimate of the additional revenue that
it would have recorded if it had acquired each of the practices
that it acquired during that period on the first day of that
period, in each case calculated in accordance with the methodology
described in the reconciliation table below.
|
Year ended Mar 31,
2022
|
|
|
(expressed in
millions of dollars)
|
|
Revenue
|
1,063.9
|
|
Add:
|
|
|
Acquisition
adjustment(5)
|
140.2
|
|
PF
Revenue
|
1,204.1
|
|
|
|
5.
|
The Company regularly
acquires dental practices and estimates that if it had acquired
each of the practices that it acquired during the LTM period ended
March 31, 2022 on the first day of the applicable period, it would
have recorded additional revenue of $140.2 million. These estimates
are based on the amount of revenue budgeted by us to be earned by
the relevant practices at the time of their acquisition by us.
There can be no assurance that if we had acquired these practices
on the first day of the applicable fiscal period, they would have
actually generated such budgeted revenue, nor is this estimate
indicative of future results.
|
PF Adjusted EBITDA
"PF Adjusted EBITDA" in respect of a period means Adjusted
EBITDA for that period plus the Company's estimate of the
additional Adjusted EBITDA that it would have recorded if it had
acquired each of the practices that it acquired during that period
on the first day of that period, in each case calculated in
accordance with the methodology described in the reconciliation
table below. PF Adjusted EBITDA is utilized by certain financial
institutions to measure borrowing capacity.
|
Year ended Mar 31,
2022
|
|
|
(expressed in
millions of dollars)
|
|
Adjusted
EBITDA
|
195.3
|
|
Add:
|
|
|
Acquisition
adjustment(6)
|
38.8
|
|
PF Adjusted
EBITDA
|
234.1
|
|
PF Adjusted
Margin
|
19.4%
|
|
|
|
6.
|
The Company regularly
acquires dental practices and estimates that if it had acquired
each of the practices that it acquired during the LTM period ended
March 31, 2022 on the first day of the applicable period, it would
have recorded additional Adjusted EBITDA of $38.8 million. These
estimates are based on the amount of Practice-Level EBITDA budgeted
by us to be earned by the relevant practices at the time of their
acquisition by us. There can be no assurance that if we had
acquired these practices on the first day of the applicable fiscal
period, they would have actually generated such budgeted
Practice-Level EBITDA, nor is this estimate indicative of future
results.
|
Adjusted Free Cash Flow
"Adjusted free cash flow" is calculated by adding or subtracting
from cash flow from operating activities: (a) external acquisition
expenses; (b) COVID-19 costs; (c) IPO costs; (d) other corporate
costs (consisting primarily of consulting costs related to our
recent ERP implementation); (e) repayment of principal on leases;
and (f) maintenance capex. We use Adjusted free cash flow to
facilitate a comparison of our operating performance on a
consistent basis from period to period, to provide for a more
complete understanding of factors and trends affecting our
business, and to determine components of employee compensation.
Adjusted Free Cash Flow is not an IFRS measure. For more
information on how Adjusted Free Cash Flow is calculated, see
below.
|
Three months
ended
|
|
March
31,
|
|
March
31,
|
|
2022
|
|
2021
|
|
$
|
|
$
|
|
(expressed in
millions)
|
Cash flow from
operating activities
|
44.0
|
|
14.1
|
Add/deduct:
|
|
|
|
External acquisition
costs
|
4.2
|
|
1.0
|
COVID-19
costs
|
—
|
|
1.0
|
IPO costs
|
—
|
|
5.9
|
Other corporate
costs
|
1.2
|
|
0.7
|
|
49.4
|
|
22.7
|
Deduct:
|
|
|
|
Repayment of principal
on leases
|
(5.6)
|
|
(5.2)
|
Maintenance
capex
|
(3.4)
|
|
(2.6)
|
Adjusted free cash
flow
|
40.4
|
|
14.9
|
Adjusted Net Income
"Adjusted net income" is calculated by adding to net loss and
comprehensive loss certain expenses, costs, charges or benefits
incurred in such period which in management's view are either not
indicative of underlying business performance or impact the ability
to assess the operating performance of our business, including: (a)
amortization of intangible assets; (b) share-based compensation;
(c) change in fair value of contingent consideration; (d) external
acquisition expenses; (e) COVID-19 costs; (f) IPO costs; (g) other
one-time corporate costs (consisting primarily of consulting costs
related to our recent ERP implementation); and (h) the tax impact
of the above. We use Adjusted net income to facilitate a comparison
of our operating performance on a consistent basis from period to
period and to provide for a more complete understanding of factors
and trends affecting our business. Adjusted Net Income is not an
IFRS measure. For more information on how Adjusted Net Income is
calculated, see below.
|
Three months
ended
|
|
March
31,
|
|
March
31,
|
|
2022
|
|
2021
|
|
$
|
|
$
|
|
(expressed in
millions)
|
Net loss and
comprehensive loss
|
(11.0)
|
|
(9.0)
|
Add:
|
|
|
|
Amortization of
intangible assets
|
20.5
|
|
17.8
|
Share-based
compensation
|
5.6
|
|
2.6
|
Change in fair value of
contingent consideration
|
11.0
|
|
(3.9)
|
External acquisition
costs
|
4.2
|
|
1.0
|
COVID-19
costs
|
—
|
|
1.0
|
IPO costs
|
—
|
|
5.9
|
Other corporate
costs
|
1.2
|
|
0.7
|
|
31.5
|
|
16.1
|
Tax impact of the
above
|
(2.9)
|
|
(3.6)
|
Adjusted net
income
|
28.6
|
|
12.5
|
Adjusted Same Practice Sales Growth
"Adjusted Same Practice Sales Growth" in respect of a period
means the percentage change in revenue derived from Established
Practices (other than Legacy Specialty Practices) plus the
Company's estimate of the impact on Same Practice Sales Growth of
the COVID-19 Omicron variant. For the three months ended
March 31, 2022 compared to the three
months ended March 31, 2021, the
Company estimates that this impact was a reduction of approximately
5.5%-6.0% which arose from patient cancellations and lost provider
days.
Same Practice Sales Growth
"Same Practice Sales Growth" in respect of a period means the
percentage change in revenue derived from Established Practices
(other than Legacy Specialty Practices) in that period as compared
to revenue from the same practices in the corresponding period in
the immediately prior year. A practice will be deemed to be an
"Established Practice" in a period if it was operating as part of
dentalcorp for the entirety of the relevant period and for the
entirety of the corresponding period in the immediately prior year.
A "Legacy Specialty Practice" means a practice acquired prior to
mid-2014 using a legacy deal structure that is no longer utilized
today.
Forward Looking Statements
This news release includes forward-looking information and
forward-looking statements within the meaning of applicable
Canadian securities legislation, including the Securities
Act (Ontario) (collectively,
"forward-looking statements"), which reflect management's
expectations regarding the Company's future growth, results from
operations (including, without limitation, future expansion and
capital expenditures), performance (both operational and financial)
and business prospects, future business plans and opportunities.
Wherever possible, words such as "plans", "expects", "scheduled",
"budgeted", "projected", "estimated", "timeline", "forecasts",
"anticipates", "suggests", "indicative", "intend", "guidance",
"outlook", "potential", "prospects", "seek", "strategy", "targets"
or "believes", or variations of such words and phrases or
statements that certain future conditions, actions, events or
results "will", "may", "could", "would", "should", "might" or
"can", or negative or grammatical versions thereof, "be taken",
"occur", "continue" or "be achieved", and other similar
expressions, have been used to identify forward looking statements.
Such forward-looking information includes, but is not limited to,
the forward-looking information related to the Canadian dental
industry; addressable markets for the Company's services;
expectations regarding its revenue and its revenue generation
potential; its business plans and strategies; and its competitive
position in its industry.
Forward-looking statements are necessarily based upon
management's perceptions of historical trends, current conditions
and expected future developments, as well as a number of specific
factors and assumptions that, while considered reasonable by
management as of the date on which the statements are made, are
inherently subject to significant business, economic and
competitive uncertainties and contingencies which could result in
actions, events, conditions, results, performance or achievements
to be materially different from those projected in the
forward-looking statements. Such factors and assumptions include,
but are not limited to, the Canadian dental industry; the Company's
ability to retain key personnel, its ability to maintain and expand
geographic scope; its ability to execute on its business plans and
strategies; its ability to obtain and maintain existing financing
on acceptable terms; changes in laws, rules, regulations and global
standards; the extent of the impact of COVID-19 and inflation on
its operations and overall financial performance and other factors
listing under the heading Risk Factors in the Company's Annual
Information Form dated March 25,
2022. While the Company considers these assumptions to be
reasonable, many assumptions are based on factors and events that
are not within its control and there is no assurance that they will
prove to be correct.
By their nature, forward-looking statements are subject to
inherent risks and uncertainties that may be general or specific
and which give rise to the possibility that expectations,
forecasts, predictions, projections or conclusions will not prove
to be accurate, that assumptions may not be correct, and that
objectives, strategic goals and priorities will not be achieved.
Known and unknown risk factors, many of which are beyond the
control of the Company, could cause actual results to differ
materially from the forward-looking statements. Such risks include,
but are not limited to, the Company's potential inability to
successfully execute its growth strategy and complete additional
acquisitions; its dependence on the integration and success of its
acquired dental practices; the potential adverse effect of
acquisitions on its operations; its dependence on the parties with
which the Company has contractual arrangements and obligations;
changes in relevant laws, governmental regulations and policy and
the costs incurred in the course of complying with such changes;
competition in the dental industry; increases in operating costs;
the risk of difficulty complying with public company reporting
obligations; and the risk of a failure in internal controls.
Although the Company has attempted to identify important factors
that could cause actual actions, events, conditions, results,
performance or achievements to differ materially from those
described in forward-looking statements, there may be other factors
that cause actions, events, conditions, results, performance or
achievements to differ from those anticipated, estimated or
intended. There can be no assurance that forward-looking statements
will prove to be accurate, as actual results and future events
could differ materially from those anticipated in such statements.
Forward-looking statements are provided for the purpose of
providing information about management's expectations and plans
relating to the future, as at the date they are provided. The
Company disclaims any intention or obligation to update or revise
any forward-looking statements whether as a result of new
information, future events or otherwise, or to explain any material
difference between subsequent actual events and such
forward-looking statements, except to the extent required by
applicable law. Accordingly, investors should not place undue
reliance on forward-looking statements. All the forward-looking
statements are expressly qualified by the foregoing cautionary
statements.
About dentalcorp
dentalcorp is Canada's largest
and one of North America's fastest
growing networks of dental practices, committed to advancing the
overall well-being of Canadians by delivering the best clinical
outcomes and unforgettable experiences. dentalcorp acquires leading
dental practices, uniting its network in a common goal: to be
Canada's most trusted healthcare
network. Leveraging its industry-leading technology, know-how and
scale, dentalcorp offers professionals the unique opportunity to
retain their clinical autonomy while unlocking their potential for
future growth. To learn more, visit dentalcorp.ca
SOURCE dentalcorp Holdings Ltd.